Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proellex in Anemic Women with Symptomatic Uterine Fibroids
NCT00785356Phase 3Terminated
- Sponsor
- Repros Therapeutics Inc.
- Start
- Oct 2008
- Primary completion
- Aug 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of telapristone in Uterine Fibroids (UF) and anemia (3 arms), sponsored by Repros Therapeutics Inc. Primary endpoint: Change in Hemoglobin From Baseline to 3 Months. Started Oct 2008; status: terminated.
02
Drugs
telapristone
03
Conditions
Uterine Fibroids (UF)anemia
Beyond the preview
Go deeper on NCT00785356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00785356.